miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
about
Impact of Nutrition on Non-Coding RNA Epigenetics in Breast and Gynecological CancerMicroRNAs, DNA Damage Response, and Cancer TreatmentPrognostic role of miR-9 expression in various human malignant neoplasms: a meta-analysisMicroRNAs Used in Combination with Anti-Cancer Treatments Can Enhance Therapy Efficacy"Back to a false normality": new intriguing mechanisms of resistance to PARP inhibitorsLow concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer.The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2.TGFβ induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genesDNA damage response markers are differentially expressed in BRCA-mutated breast cancersmiR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.Depletion of eIF2·GTP·Met-tRNAi translation initiation complex up-regulates BRCA1 expression in vitro and in vivo.Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA ExpressionMitochondrial fission determines cisplatin sensitivity in tongue squamous cell carcinoma through the BRCA1-miR-593-5p-MFF axis.miR-9 Acts as an OncomiR in Prostate Cancer through Multiple Pathways That Drive Tumour Progression and Metastasis.Prognostic value of microRNA-9 in cancers: a systematic review and meta-analysis.MicroRNA Gene Expression Signature Driven by miR-9 Overexpression in Ovarian Clear Cell Carcinoma.Micro-RNAs associated with the evolution of ovarian cancer cisplatin resistance.A chemotherapy response classifier based on support vector machines for high-grade serous ovarian carcinomaEffect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.MicroRNA deregulation in triple negative breast cancer reveals a role of miR-498 in regulating BRCA1 expression.Regulation of multidrug resistance by microRNAs in anti-cancer therapyMiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinomaLet-7e sensitizes epithelial ovarian cancer to cisplatin through repressing DNA double strand break repair.Epigenetic perspectives on cancer chemotherapy response.Ovarian cancer: diagnostic, biological and prognostic aspects.miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.MicroRNA in Ovarian Biology and Disease.miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.Targeting mitotic pathways for endocrine-related cancer therapeutics.MicroRNAs and cancer resistance: A new molecular plot.Recently identified drug resistance biomarkers in ovarian cancer.miR-9 promotes cell proliferation and inhibits apoptosis by targeting LASS2 in bladder cancer.The role of exosomes and miRNAs in drug-resistance of cancer cells.MicroRNA-mediated drug resistance in ovarian cancer.Propofol inhibits invasion and growth of ovarian cancer cells via regulating miR-9/NF-κB signal.Plasma microRNA-9 as a diagnostic and prognostic biomarker in patients with esophageal squamous cell carcinomaThe potential role of miRNAs in therapy of breast and ovarian cancers associated with BRCA1 mutation.Overexpressed miR-9 promotes tumor metastasis via targeting E-cadherin in serous ovarian cancer.The Double Face of Exosome-Carried MicroRNAs in Cancer Immunomodulation.C/EBPβ enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation.
P2860
Q27016123-B240A178-6A0E-4AAD-A388-F7798930B84AQ28067062-41A114F3-1EB9-40A4-A421-0335CED4C982Q28079614-8D36DB46-3E68-4A34-BF76-B1CBB15C2EF1Q28829013-1A84539D-1F7E-47FD-8C64-0E12C86140D0Q33618910-458CE5F1-617B-4F5F-993C-9684E88228CFQ33856711-FBE00E26-8C62-4E57-B463-0D7FAE525378Q34455481-1274EB07-9433-4397-841B-C011C11A4A66Q34518332-716B51B1-B604-48A2-A359-9C59EEDBA129Q35131267-D7D96B63-CC7B-464C-83E8-AA078BEF098EQ35225778-4C11BCF4-7A62-449D-9201-3B430AFA7596Q35740103-AD56CBB7-7749-4C35-B33C-C6E98992F734Q35767389-340003DC-193F-4066-B97C-D836B370BC70Q36020872-973A7F14-6691-421E-978D-68C2A3B36DCCQ36083567-275163B9-055F-42D3-BD2E-B9063C7B0F08Q36114010-5F22C6F2-EC4E-406A-BFF7-B8F61A8D291FQ36128575-7E570D6E-6A50-4A09-B6AD-AFB8BCD2E8F2Q36494718-7157F0EA-14DA-466B-ADB6-D64DE75E6620Q36772106-3CDD4B2D-1232-4B46-8B8B-E986B53EA701Q36878642-676CE1AB-2391-4732-A5F7-D7803399F69AQ37190254-34878B36-4D57-427E-8647-7708E51DE8F1Q37587311-F9A7E9F9-39CB-4594-9B52-3C5F414B64D8Q37706681-75B75D1B-41B7-4FD7-A8F1-26BB2B660A08Q37736667-F48F0727-56D2-4867-9C80-72EA5F109F22Q38209574-F5C90833-CB38-4FE8-93EE-F4A4A9FF9C46Q38261795-938AD9F1-BB40-4BC4-B20A-3F15376161D4Q38366731-AB4D6E09-81ED-4CE5-8AC1-4B508810D1A8Q38489481-FB2CDF8F-4134-4368-BDD3-A2A6475C9A3AQ38633144-05301638-707E-4E70-9669-9992D098E172Q38671036-BF53C9DF-6B8E-4AEB-B13D-41E11B1346FAQ38732712-B871BD34-142D-49C3-BCB9-318752E31849Q38741073-1F606D5D-139B-4060-8059-CD83C6472D03Q38856001-575006C7-ED03-43B0-9AA5-1C1C053E1DDBQ39152624-B3A48FA2-7757-4CB6-87E3-7F194B568DDEQ39382756-C248613B-FDCC-4564-A2FC-C9ECFDA94D8EQ39959213-0CDAD68C-370B-4B53-B722-906A1E084337Q41848455-C3C8F05E-EC4B-42C1-BFB0-2809552F459AQ42368096-D2611E50-B2D3-4EC5-A8A6-4272C1D48367Q51021300-EF785524-C291-473E-8BE4-382A6E166846Q52589944-760341A4-DD61-4163-8AF0-2A2647516ADEQ53689778-1BC14087-BD26-4644-8157-75ECB020D472
P2860
miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@ast
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@en
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@nl
type
label
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@ast
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@en
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@nl
prefLabel
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@ast
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@en
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@nl
P2093
P2860
P356
P1476
miR-9 regulation of BRCA1 and ...... cisplatin and PARP inhibition.
@en
P2093
Chaoyang Sun
Danhui Weng
Jianfeng Zhou
Pingbo Chen
Xiaokui Yang
P2860
P304
P356
10.1093/JNCI/DJT302
P407
P577
2013-10-29T00:00:00Z